Nurix Therapeutics, Inc. (NRIX) AI Stock Analysis

Nurix Therapeutics, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing small molecule therapies that target critical pathways in disease progression. Its clinical pipeline features NX-2127 and NX-5948, which are orally available Bruton's tyrosine kinase (BTK) degraders designed to address B-cell malignancies and autoimmune diseases. The company is also advancing CBL-B inhibitors, including NX-1607 for immuno-oncology applications, NX-0255 for ex vivo use in adoptive T-cell therapy, and DeTIL-0255 in Phase 1 clinical trials for gynecologic cancers such as ovarian, endometrial, and cervical cancer. Nurix maintains strategic collaborations with industry partners including Gilead Sciences, Inc. and Sanofi S.A.

Nurix Therapeutics expanded annual revenue from $29.8M in FY2021 to $38.6M in FY2022 and $77.0M in FY2023. Annual revenue dipped to $54.5M in FY2024 before rising 54.0% to $84.0M in FY2025, reflecting a 5-year revenue CAGR of 36.3%. In FY2025, operating margin was -340.2%, net income was -$264.5M, and eps was -$3.04. Over the trailing twelve months ended August 31, 2026, performance shifted significantly to revenue of $701.9M, eps of $2.43, and an operating margin of 83.1%, driven by latest quarterly revenue growth of 8426.3%.

As of August 31, 2026, Nurix Therapeutics held $1.05B in cash and short-term investments against total debt of $65.3M, resulting in net cash of $982.9M. Total assets reached $1.20B, shareholders' equity stood at $968.3M, and the current ratio was 8.44 with a debt-to-equity ratio of 0.07. In FY2025, operating cash flow was -$249.5M, free cash flow was -$263.5M, and capital expenditures were $14.0M. The company's 5-year share count change was 160.7%.

Nurix Therapeutics trades at a trailing price-to-earnings multiple of 10.0x, below the 24.6x median of its US-listed Healthcare peers. Its price-to-sales multiple is 3.8x compared to the peer median of 4.1x, while enterprise value to revenue stands at 56.9x. The company carries a market cap of $2.67B and an enterprise value of $2.09B. Over the past year, the stock returned 143.5%, outperforming the 16.8% return of the S&P 500. Over 5 years, the stock returned -15.3% against an 83.0% gain for the S&P 500.

Wall Street analysts have issued 8 Strong Buy, 5 Buy, and 1 Hold ratings on the stock. The mean price target is $34.50, implying an upside of 41.3% from the last close of $24.42. For the fiscal year ending November 30, 2026, consensus estimates project revenue of $744.8M and eps of $3.02, reflecting eps growth of 199.0%. For the next fiscal year, 3 analysts project revenue of $123.2M and eps of -$1.28. Over the last 4 quarters, the company recorded 3 eps beats.

This page is an AI-written research summary of Nurix Therapeutics, Inc. (NRIX). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: NRIX income statement, NRIX balance sheet, NRIX key metrics, NRIX analyst forecast, NRIX chart. See the NRIX stock overview for the latest quote and news.